Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
180,000 on the bid, nice.
No 10Q in mid May.
Next report will be end of June.
Elite's schedule goes something like this:
10Q - 2/14
10K - 6/30
10Q - 8/14
10Q - 11/14
It relates to the Epic agreement....10.17
Maybe Schedule B changed, not sure...maybe someone can give a closer look.
Might be a prelude to Isradipine announcement Monday?
Here is Schedule B...
SCHEDULE B
Compensation for Licensing Rights
Milestone Payments
EPIC shall pay to ELITE Milestone Payments totaling $1,800,000, according to the following schedule:
License Fee
EPIC will pay to ELITE a License Fee that is a percentage of the product gross profit (“Product Gross Profit”) of EPIC, as defined below,
generated on Products sold and shipped to its customers by EPIC according to the following schedule:
Product Gross Profit is defined as:
Net Sales – Cost of Sale - Cost of Goods = Product Gross Profit.
{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment
request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Confidential
• $600,000 shall be due to ELITE upon signing of this License Agreement and shall be paid no later than November 15 th , 2013.
• $ {***} shall be paid to ELITE upon filing for each Product’s supplement with FDA as listed below:
• {***}
• {***}
• {***}
• $ {***} shall be paid to ELITE five business days after FDA’s approval of the site transfer or first product launch and/or shipment
whichever comes first:
{***}
{***}
{***}
• 50 % of Product Gross Profit
Net Sales is defined as: Net Invoice Price less the following: Charge backs, Buying Groups/Wholesaler Administrative
Fees/Rebates, Allowances, Medicaid and Returns.
Cost of Sales is defined as 3% of Net Sales
Cost of Goods is defined as $ {***} per 1000 units in any configuration required by marketing plus the cost of the API at cost
(as documented by invoices for the API).
Just do the math.
The dividend is based on shares owned 4/10 no?
Elite one of two US makers of Isradpine. $6,000,000 market now. What will it be if this pans out?
===============================================================
http://www.urmc.rochester.edu/news/story/index.cfm?id=4042
Researchers Set to Launch Phase 3 Trial for Parkinson’s
April 02, 2014
A $23 million grant from the National Institutes of Health will support a new Phase 3 clinical trial to evaluate the drug isradipine as a potential new treatment for Parkinson’s disease. The study is being co-lead by the University of Rochester and Northwestern University.
“Isradipine has been demonstrated to be safe and tolerable in patients with Parkinson’s disease,” said University of Rochester School of Medicine and Dentistry neurologist Kevin Biglan, M.D., co-principal investigator of the study. “This new study will determine whether the drug can be an effective tool in slowing the progression of the disease and could, thereby, complement existing symptomatic treatments and improve the quality of life of individuals with the disease.”
“If it proves to be effective, this drug will change the way we treat Parkinson’s disease, and the major advantage of it is that isradipine is already widely available, inexpensive and will allow for rapid translation of our research into clinical practice,” said Tanya Simuni, M.D., principal investigator of the study, professor of neurology at Northwestern University Feinberg School of Medicine. “Although we now have very effective symptomatic treatments to manage Parkinson’s, the development of a disease-modifying intervention remains a critical goal.”
Isradipine is a Food and Drug Administration-approved drug to treat high blood pressure. Researchers suspect that the drug may also be effective in treating Parkinson’s for a couple reasons. First, population scale studies have shown that people taking the drug for high blood pressure have a lower incidence of Parkinson’s disease. Additionally, isradipine is in a category of drugs called calcium channel blockers, meaning they inhibit certain cellular functions. Researchers speculate that overactive calcium channels may play a role in the death of the dopamine producing cells in the brain that is one of the hallmarks of Parkinson’s.
Parkinson's disease is a progressive neurological disorder that erodes an individual’s control over their movements and speech. Over time, Parkinson’s patients experience stiffness or rigidity of the arms and legs, slowness or lack of movement, and walking difficulties, in addition to tremors in their hands, arms, legs, jaw or face.
A Phase 2 evaluation of isradipine, which was conducted to determine the safety and appropriate dosage for the drug, was completed in 2012. The study was funded by a $2.1 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), which also supported preclinical research into the effects of isradipine on Parkinson’s progression by Northwestern University.
“Our de-risking model quickly advances promising research ideas toward larger investment and, thereby, closer to clinical application,” said MJFF CEO Todd Sherer, Ph.D. “The NIH funding to continue testing of isradipine brings us one step closer to a disease-modifying therapy that could make a real difference in the lives of millions.”
The new clinical trial – titled STEADY-PD3– will recruit 336 individuals with Parkinson’s disease at 56 sites throughout North America, including the University of Rochester. The study – which is scheduled to begin recruiting Parkinson’s patients later this year – will follow the participants for three years. The primary goal of the study is to determine whether the drug can slow the progression of the disease.
Physicians currently have several tools at their disposal that enable them to effectively manage the symptoms of the disease for a period of time, however, no treatment exists that can slow the progressive deterioration of function. Consequently, many patients diagnosed with Parkinson’s will experience a “honeymoon” period of two to five years during which existing treatments can essentially help them to lead a normal life. But over time, these treatments become less effective.
One of the goals of Parkinson’s research is to identify new therapies – such as isradipine – that could slow the advance of the disease by keeping the brain’s dopamine-producing cells healthier for a longer period of time. Researchers believe that the development of disease modifying approaches – commonly referred to as neuroprotection – and new ways to monitor the progress of the disease when complemented with existing symptom-managing therapies could help hold disability at bay.
“We have good early stage treatments for the symptoms of Parkinson’s disease and individuals who have problems with mobility and coordination can often get back to where they can function at a very high level,” said Biglan. “However, over the long term problems arise due to disease progression and people become less responsive to therapy. If you could slow the progression sufficiently enough, then with existing symptomatic treatments you could manage Parkinson’s symptoms quite well over a much longer period of time.”
STEADY-PD3 – which is being funded by the National Institute of Neurological Disorders and Stroke – will involve researchers from the Parkinson Study Group , which was founded in 1986 and consists of more than 400 active investigators, coordinators, and scientists located at 126 institutions throughout the United States and Canada. The University of Rochester’s Center for Human Experimental Therapies will provide project management and data coordination for the study and David Oakes, Ph.D., with the Department of Biostatistics will serve as lead biostatistician. Carematix will support clinical trial operations including data management and real time uploading of blood pressure readings from patients at home. Verizon Enterprise Solutions will provide the communications technology that enables the exchange of data so that patient information can be securely transmitted to researchers for analysis and interpretation.
Way too many catalysts on deck for ELTP.
All I can say is "filter enabled" really helps.
The 4/15 S-3 for LPC deal had copies sent to:
Copies to:
Richard Feiner, Esq
381 Park Avenue South, 16 th Floor
New York, NY 10016
212-779-8600
917-720-0863 (fax)
Don't know if that means anything though.
And the boards vote was u·nan·i·mous...
Look it up
It was a unanimous vote. Don't see FDA going against that.
ELITE PHARMACEUTICALS GRANTED NEW PATENT FOR ABUSE DETERRENT TECHNOLOGY
NORTHVALE, N.J. – April 22, 2014 – Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB: ELTP) announced today the issuance of U.S. Patent No. 8,703,186 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof”. This patent expands the intellectual property for the Company’s opioid abuse deterrent technology. Elite now has three US patents and one Canadian patent issued in this area with additional patents pending in the U.S., Canada and Europe.
"We are pleased with this additional patent coverage,” stated Nasrat Hakim, President and CEO of Elite. "Elite’s abuse deterrent program has made significant progress. In December, a successful pilot bioequivalence study for ELI-201 was completed and in January a successful pivotal bioequivalence study for ELI-200 was completed. These products are the first of our many abuse deterrent opioid products under development.”
About Elite’s Abuse Deterrent Technology
Elite’s abuse deterrent products utilize the Company’s proprietary pharmacological abuse deterrent technology. Elite’s abuse deterrent technology is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist. Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has seven commercial products currently being sold, twelve additional approved products pending manufacturing site transfer and two additional products under review pending approval by the FDA. Elite’s lead pipeline products include abuse resistant opioids utilizing the Company’s patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.) and has partnered with Epic Pharma for the manufacturing and distribution of eleven approved products pending manufacturing site, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
This news release contains "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, its ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These risks and other factors, including, without limitation, the Company’s ability to obtain sufficient funding under the LPC Agreement or from other sources, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, intellectual property protections and defenses, and the Company’s ability to operate as a going concern, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite undertakes no obligation to update any forward-looking statements.
Contact:
Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
Couch, correct me if I am wrong but as I understand it we won't hear anything from the FDA unless there is an objection. If there is no objection after 30 days Elite can move forward.
see below:
Similar to Changes Being Effected (CBE). A filing with the FDA to gain approval of a moderate change, i.e., a change that has a moderate potential to have an adverse effect on the identity, strength, quality, purity, or potency of the drug product as these factors may relate to the safety or effectiveness of the drug product. FDA has 30 days to respond prior to implementation of the change. If filer receives no word from FDA in 30 days, it is assumed that the change was approved. See also Changes Being Effected and Prior Approval Supplement. - See more at: http://www.contractpharma.com/contents/view_glossary/2013-03-25/cbe-30/#sthash.jZ3xS4u5.dpuf
FDA wants stronger warning labels for long-acting opioids
Reuters
http://finance.yahoo.com/news/fda-wants-stronger-warning-labels-170851227.html
1 hour ago
By Ransdell Pierson
April 17 (Reuters) - The U.S. Food and Drug Administration is requiring labels of all long-acting opioids to say they should be used strictly for patients in severe pain, a response to surging overdoses and deaths each year from the widely used pain medicines.
The health regulator in September proposed the label changes, saying they were needed to highlight dangers of abuse and possible death, as well as risks to newborns of mothers taking the medicines. [ID: nL2N0H61AW]
The FDA, in a notice on its website on Wednesday, said it had approved the proposed changes, which will indicate that such drugs should only be used for severe pain. Currently, the labels indicate they are appropriate for patients with moderate and severe pain.
Opioids include formulations of morphine, oxycodone, fentanyl and Oxycontin, a long-acting form of oxycodone. They currently are widely prescribed, including for patients that have had dental or surgical procedures, or those complaining of back pain or headaches. Extended-release opioids will also fall under the proposed FDA guidelines.
Updated language on the drug labels will stress the medicines are meant for pain severe enough to require daily, round the clock, long-term opioid treatment, and only for those who have not had adequate pain relief from alternative medicines.
The labels will also include prominent warnings that chronic maternal use of the drugs can result in potentially fatal opioid withdrawal syndrome in newborns.
New opioids continue to be introduced, including a long-acting form of hydrocodone called Zohydro, made by Zogenix Inc, that has stirred controversy among U.S. politicians, prosecutors and medical societies.
The FDA approved Zohydro in October despite concerns by the agency's medical advisory panel over its potential for abuse. The 12-hour capsules can be crushed and inhaled or injected, making a full dose available immediately, according to critics.
Zogenix maintains the drug is a necessary option for patients with severe, around-the-clock pain who cannot tolerate acetaminophen.
Massachusetts Governor Deval Patrick last month announced a ban on Zohydro, formally declaring a public health emergency stemming from abuse of opioids in the state. But a federal court judge on Tuesday reversed the ban, saying Massachusetts was obstructing the FDA's constitutionally mandated authority.
More than 16,000 people in the United States died in 2010 from overdose deaths related to opioid abuse, according to the FDA, with long-acting forms of opioids playing a "disproportionate role" in drug abuse and deaths.
Although the updated language for long-acting opioids will be more restrictive, the FDA has acknowledged the agency really has no ability to ensure that doctors actually restrict their prescriptions to patients with severe pain.
"The FDA does not have the authority to regulate the practice of medicine, and health care practitioners may choose to prescribe a legally marketed drug, based on their clinical assessment," FDA spokeswoman Morgan Liscinsky said in September, when the label changes were proposed.
Another worrisome aspect of opioids is their link to burgeoning heroin addiction in the United States, in cities and towns of all sizes.
Healthcare and law enforcement experts say many people, including teenagers and young adults, become addicted to opioids found in their family medicine cabinets or elsewhere, and then turn to far-cheaper heroin when they no longer have access to the opioids or cannot afford them.
(Reporting by Ransdell Pierson; Editing by Bernard Orr)
Very well said
I will be there
I received an email from E Trade this morning:
Dear Valued Customer,
You elected to receive shareholder communications and submit voting instructions via
the Internet. This e-mail contains information specific to your holding in the securities
identified below.
Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting
2014 ELITE PHARMACEUTICALS, INC. is holding an Annual Meeting of Stockholders as follows:
MEETING DATE: May 21, 2014
For Holders as of: March 28, 2014
CUSIP NUMBER: 2865xxxxx
ACCOUNT NUMBER: ****
CONTROL NUMBER: 575xxxx2
You can enter your voting instructions and view the shareholder material by clicking
on the following link:
https://www.proxyvote.com/xxxxxx
For our secure site:
https://www.proxyvote.com/xxxxxx
Internet voting is accepted up to 11:59 p.m. (ET) the day before the meeting/cut off date.
Additional supporting documentations can also be found at the following link(s):
Proxy Statement
http://www.elitepharma.com/annual_meeting.asp
10-K Report
http://www.elitepharma.com/annual_meeting.asp
Third Quarter Report
http://www.elitepharma.com/annual_meeting.asp
Shareholder Letter
http://www.elitepharma.com/annual_meeting.asp
To view the documents above, you will need the Adobe Acrobat Reader. If you do not currently have this
program on your system, you can download it now: http://www.adobe.com/products/acrobat/readstep2.html
To view, cancel or change your enrollment profile,
please go to https://us.etrade.com/e/t/accounts/accountprofile.
Ditto. Voted as the board recommended.
April 3, 2014
Dear Fellow Shareholders,
Having been a long time shareholder and close follower of Elite, it is an honor to be writing my first letter to our shareholders as Elite’s President and Chief Executive Officer. As steward of your Company, my primary focus has been to achieve long-term company growth through prudent execution of strong and effective business strategies. My plans for Elite when I became President and CEO last August were 1) to grow our generic pharmaceutical business and 2) to move forward with urgency to develop and commercialize Elite’s proprietary opioid abuse deterrent products. Since August, we have successfully been executing this plan.
Elite’s generic business segment was enhanced this year by the acquisition of twelve approved generic products and then by the launch of two additional generic products. The newly acquired products have in turn been licensed out for upfront money and an attractive profit sharing arrangement. A site transfer has already been filed with the U.S. Food and Drug Administration (FDA) for the first of these new products, and the transfer of the other eleven products is on track. These additions to the generic business have greatly strengthened the profitability of this segment of Elite’s business. I expect the rapid growth of the generics to continue as the current commercial products grow and the twelve new products are launched.
The really significant change for Elite this year, however, was the accelerated development of the opioid abuse deterrent products. It is these products where I see a tremendous upside potential to create value for you, our shareholders. We have two opioid abuse deterrent products, ELI-200 and ELI-201, in human trials and an additional five abuse deterrent formulations under active development. We are very pleased with the success of the product trials in recent months. The ELI-201 pilot study showed that more than one of Elite’s formulations was bioequivalent to the brand product, and the ELI-200 pivotal study demonstrated bioequivalence of Elite’s product to the reference product. We expect to file our first abuse deterrent New Drug Application (NDA) with the FDA this year and we then expect to file additional NDAs the following year. We have also received further protection for these abuse deterrent products with the issuance of two patents, an additional patent allowed in the U.S. and the issuance of one Canadian patent in recent months. We have additional patents filed and pending in the U.S., Canada and Europe. Elite’s technology can be applied to any of the current opioids in the market place, and our goal is to broadly use our technology to reduce the current epidemic of prescription drug abuse.
To permit Elite to execute on our initiatives, I am asking in this proxy for an increase in authorized shares. These additional shares will allow Elite to continue to fund development of our abuse deterrent products, and will give us flexibility to launch our first abuse deterrent product on our own, if we believe that to be in the best interest of the company and its shareholders. I am also actively pursuing partnership opportunities for our abuse deterrent products, but the further we can develop a product, the more favorable terms I expect to receive for the product(s). Additional authorized shares will provide options and flexibility to Elite in order to unlock the value of our assets.
Please remember that as a shareholder, your vote is extremely important to the Company no matter how many shares you own. For certain very important resolutions, failure to vote or specifically direct your broker to vote, would be considered the same as a “NO” vote. Please take a few moments to vote whether or not you plan to attend the Annual Meeting. You can vote by completing, signing, dating and promptly returning the enclosed proxy card. Alternatively, you may vote through the Internet or by telephone as directed on your proxy card. If you receive more than one proxy card because you own shares that are registered differently, please vote all of the shares shown on all of your proxy cards.
If you have any questions or need assistance voting your shares, please call our proxy solicitor, Morrow and Co toll free at 855-251-9340 or Dianne Will, Investor Relations for Elite Pharmaceuticals at 518-398-6222.
I thank each of you for your tremendous support during this year, and we look forward to continued success.
Nasrat Hakim
President and Chief Executive Officer
Most here did not buy in the 0.06s just try hard and remember that.
Ummm, how do you know that?
Please, this is a place for ELTP DD sharing, not speculative nonsense.
Off hand?
You have to know the market value of the 1st ART drug and decide a probable market share and profit on it......then determine the share count w/o further dilution...get your projected value.
Then project 15 ART drugs w/ dilution.
I think 15X the drugs vs maybe 30% more dilution kind of answers itself.
Don't kill me on the math...just throwing out a frame of reference.
When you get your email notification from Elite this is where you can vote online.
https://secure.amstock.com/voteproxy/login2.asp
and will give us flexibility to launch our first abuse deterrent product on our own,
I agreed. Very succinctly stated by both you and the king.
In my opinion this is very well grounded speculation.
Of course it is. Do you have a link to prove that?
In your opinion
Agreed
Dead horse is quite beaten
Never said that.
I thought you were a member of the profession?
Depends on ones definition of better.
The definition in your example is not necessarily "better".
Bioequivalence is defined in 21 CFR 320.1 as the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study
You see. "absence of a significant difference"
So, yes it could be different, even better. Perhaps not significantly so, but it can be better.
It's all in the semantics no?
Let it go. Game over.
Oh goody, so do I.
I can tell you the same. Funny how that works.
You saw the studies?
Why is this a sticky?
Zohydro ER exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death.
http://www.zogenix.com/content/products/zohydro.htm
Heavens, the product was banned? Wow, just wow.
They better get going on the Abuse Resistant product.
If they can't sell their product and therefore can't fund R&D and trials for the AR product how will they come up with the money? Will they have to use dilutive financing?
http://seekingalpha.com/instablog/24448293-stealdealbroker/2788223-what-the-fda-and-the-future-of-drugs-nsfw?source=kizur_seekingalpha
What The FDA! And The Future Of Drugs [NSFW] 0 comments
Mar 28, 2014 12:47 PM | about stocks: ELTP, PFE, ENDP, ZGNX
Scroll down to bottom if TLDR;
If you haven't been living under a rock in the past few months then most likely you've heard about the controversy about Zogenix's Zohydro and their head-butting with substance abuse programs. This three part series turned into one because everyone hates sequels more than trilogies is going to have you scratching yourself in so many places you'll make opiate addicts look normal.
Before I get into any of this, here's a quick fun fact for all you readers that will surprise you, 1 out of 20 people reading this have railed, popped, parachuted or even shot some sort of dose of opiate based drug in the past 6 hours. So look around your office and see if any of your colleagues pupils are pinpoint small, hell, maybe you'll be lucky to find an oxy that fell out of a purse of briefcase and rolled next to your desk.
So why is Zogenix in the news when BIG PHARMA companies such as Purdue, Pfizer, Endo, and others aren't? This article will touch on some interesting investment points as well as a whole lot of facts you probably didn't know or just didn't care for but that's enough paragraph foreplay for now, lets get into the dirty D, drugs that is..
Well, let me begin this first series with WTF. What the FDA? We all know what it stands for and if you don't (duckduckgo.com) it. And what's all this mish-mosh speak about ABUSE DETTERANT? ABUSE DETTERANT is simply a formula added to a drug that makes it more difficult to abuse, but more to come below.
Why is the FDA getting so much shit lately from the BIG PHARMA lobbyists and abuse and misuse programs? Zogenix's new drug Zohydro can be easily be misused, just like many other opiate based drugs. Just crush it snort it shoot it and feel great right? Well what about Oxycontin, Roxycontin, Opana and many other drugs that your 16 year old kids can find for $12-$50 a pill on the streets?
These BIG PHARMA (which some people believe are legal heroin dealers but I won't get into that right now) have already paid their dues and have began creating ABUSE DETERRANT formulas to include in FUTURE DRUGS.
THATS RIGHT FOLKS, you've heard it here first. The FDA is slowly waking up and realizing that these pain killers are equivalent to HEROIN and it's only time before one of their loved ones are a victim to opiate abuse before they MANDATE ABUSE DETERRANT formulas in opiate based drugs, or maybe not, maybe they already have young ones that are buying these drugs in the street and shield them so they don't bring shame onto themselves. Maybe one day one of these kids will speak out and create waves in the market and when it happens GET READY!
These BIG PHARMAs, already mentioned, have created abuse deterrent opiates, Remoxy and Opana Gels are out on the market but people adapt and always find a NEW way to abuse them. Take ENDO PHARMAs OPANA for example. Our analysts researched into forums and found that people have found a way to abuse OPANAs. I won't get into detail but these drug companies have failed to test the ABUSE PHASE of the ABUSE DETTERANT formula and in turn made abusing their opiates just slightly inconvenient. You'd think that these genius scientists who are getting paid thousands would know this and this is what is worrisome.
Let's say you're invested in Zogenix and the FDA did BAN all DRUGS WITHOUT ABUSE DETTTERANT FORMULAS. You can kiss your stock goodbye. If a ban on Zohydro in the US happened tomorrow that stock would be depleted faster than your cell phone battery in a puddle of bum piss.
What's the future of Pharma and ABUSE DETTERANT DRUGS? Our analysts researched many companies and have found one particular to be some what interestingly promising. Elite Pharmaceuticals has developed VERY promising formulas to license out to generics. This company is currently trading at .43 as this is being written and you can bet your sweet opiate asses I'm invested in this and will be continuing to closely watch as this stock should be trading around the $12 mark if the FDA declares a mandatory ABUSE DETTERANT formula for opiate drugs.
TLDR; People missuse drugs even with new formulas. ELTP is changing that. FDA might look to change laws for Opiate drugs.
Disclosure: I am long ELTP.
Additional disclosure: and will be invested in it for the long run. This article is intended for you to make decisions based on your own research. If you were offended in this article in any way we are not sorry. Tweet us @StealDealBroker
I might agree if I knew what that meant....
Wow, so tie back everything Nanotech ever did to Dave Foley who no longer works there. Wow.